Cervical Cancer - Pipeline Analysis and Market Forecasts to 2016

Jan. 6, 2010 - PRLog -- GlobalData has estimated the global cervical cancer market to be valued at $1.8 billion in 2009. It is expected to grow to $4.1 billion by 2016, at a Compound Annual Growth Rate (CAGR) of 11.9% between 2009 and 2016. This growth is primarily attributed to increased competition among the existing cervical cancer vaccines in the market. The vaccines will be primarily responsible for the growth of the market with the predicted increase in their uptake and sales. The success of these vaccines has driven a lot of companies into research activity.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Cervical-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData analyzed that there are over 44 molecules in various stages of the pipeline. The pipeline shows activity both in the area of prevention and drug treatment. The late stage pipeline for cervical cancer has fewer options and lacks novelty. In Phase III, there are mainly combination therapies that are being carried out with Cisplatin. The novel therapeutic vaccines are still in the early stages of development. The lack of options and novelty in the Phase III stage makes the pipeline weak. Weak options in the late stage of the pipeline indicate that the future market activity will primarily be dominated by the existing options in the market. Competition between these vaccines will lead to a market share war between them.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID...

GlobalData analyzed that the current competition in the cervical cancer market is becoming more intense due to increased competition between two cervical cancer vaccines. Both the vaccines, Gardasil and Cervarix, are trying to overtake the market share of each other. Merck’s Gardasil, which has been in the market for a long time, is facing competition from GSK’s Cervarix which was approved in 2009 in the US. There is competition between them to expand the label indications, to provide broader coverage against the HPV strains, for inclusion in national immunization schedules around the world. These two vaccines form the major cervical cancer market activity and the drugs have a very limited role in the activity of the current market. These vaccines will be responsible for major future market growth also.

GlobalData, the industry analysis specialist’s new report, “Cervical Cancer – Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global cervical cancer market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global cervical cancer sector.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Cervical-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016


Or visit our report store: http://www.globaldata.com/reportstore

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.